The Union League of Philadelphia
140 South Broad Street
Philadelphia, PA 19102

Date: Wednesday, June 26, 11:30 am to 1:00 pm

Program Presenter: Robb Knie, President and Chief Executive Officer, HOTH Therapeutics, Inc.

Robb Knie, President and Chief Executive Officer

Robb Knie has served as President and Chief Executive Officer and as a director of the Company since May 2017 and served as our principal financial and accounting officer from June 2018 until March 2019. Mr. Knie served as the President of Lifeline Industries Inc. since its inception in 1995. From 2002 to 2010 he was a Semiconductor Analyst for PAW Partners.

From 1993 until 1995, Mr. Knie served as Northeast Regional Manager of American Express Financial Advisors. Mr. Knie served as a board member of Inventergy Global, Inc. (NASDAQ: INVT) from December 2013 until October 2014. We believe that Mr. Knie is qualified to serve as a director because of his business and leadership experience and experience as a board member of public companies.


Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.


BioLexa platform technology is a patented topical agent that combines a chelating agent with an antibiotic in a proprietary formula, to fight bacterial infections across multiple platforms.

The current formulation has applicability in the areas of:

  • Eczema
  • Aesthetic dermatology
  • Urgical site infections
  • Chronic wound care
  • Chronic diabetic wound care